Materna V - Search Results

1

Protection of platinum-DNA adduct formation and reversal of cisplatin resistance by anti-MRP2 hammerhead ribozymes in human cancer cells.

Materna V, Liedert B, Thomale J, Lage H. Materna V, et al. Int J Cancer. 2005 Jun 20;115(3):393-402. doi: 10.1002/ijc.20899. Int J Cancer. 2005. PMID: 15688364

2

Overexpression of cMOAT (MRP2/ABCC2) is associated with decreased formation of platinum-DNA adducts and decreased G2-arrest in melanoma cells resistant to cisplatin.

Liedert B, Materna V, Schadendorf D, Thomale J, Lage H. Liedert B, et al. Among authors: materna v. J Invest Dermatol. 2003 Jul;121(1):172-6. doi: 10.1046/j.1523-1747.2003.12313.x. J Invest Dermatol. 2003. PMID: 12839578 Free article.

3

RNA expression of MDR1/P-glycoprotein, DNA-topoisomerase I, and MRP2 in ovarian carcinoma patients: correlation with chemotherapeutic response.

Materna V, Pleger J, Hoffmann U, Lage H. Materna V, et al. Gynecol Oncol. 2004 Jul;94(1):152-60. doi: 10.1016/j.ygyno.2004.03.035. Gynecol Oncol. 2004. PMID: 15262134

4

RNA interference-triggered reversal of ABCC2-dependent cisplatin resistance in human cancer cells.

Materna V, Stege A, Surowiak P, Priebsch A, Lage H. Materna V, et al. Biochem Biophys Res Commun. 2006 Sep 15;348(1):153-7. doi: 10.1016/j.bbrc.2006.07.022. Epub 2006 Jul 14. Biochem Biophys Res Commun. 2006. PMID: 16876126

5

Complete reversal of ABCG2-depending atypical multidrug resistance by RNA interference in human carcinoma cells.

Priebsch A, Rompe F, Tönnies H, Kowalski P, Surowiak P, Stege A, Materna V, Lage H. Priebsch A, et al. Among authors: materna v. Oligonucleotides. 2006 Fall;16(3):263-74. doi: 10.1089/oli.2006.16.263. Oligonucleotides. 2006. PMID: 16978089

6

ABCC2 (MRP2, cMOAT) can be localized in the nuclear membrane of ovarian carcinomas and correlates with resistance to cisplatin and clinical outcome.

Surowiak P, Materna V, Kaplenko I, Spaczynski M, Dolinska-Krajewska B, Gebarowska E, Dietel M, Zabel M, Lage H. Surowiak P, et al. Among authors: materna v. Clin Cancer Res. 2006 Dec 1;12(23):7149-58. doi: 10.1158/1078-0432.CCR-06-0564. Clin Cancer Res. 2006. PMID: 17145840

7

Nuclear metallothionein expression correlates with cisplatin resistance of ovarian cancer cells and poor clinical outcome.

Surowiak P, Materna V, Maciejczyk A, Pudełko M, Markwitz E, Spaczyński M, Dietel M, Zabel M, Lage H. Surowiak P, et al. Among authors: materna v. Virchows Arch. 2007 Mar;450(3):279-85. doi: 10.1007/s00428-006-0362-7. Epub 2007 Jan 19. Virchows Arch. 2007. PMID: 17235562

8

Kinetic characterization of ribozymes directed against the cisplatin resistance-associated ABC transporter cMOAT/MRP2/ABCC2.

Materna V, Holm PS, Dietel M, Lage H. Materna V, et al. Cancer Gene Ther. 2001 Mar;8(3):176-84. doi: 10.1038/sj.cgt.7700293. Cancer Gene Ther. 2001. PMID: 11332988

9

Homozygous mutation Arg768Trp in the ABC-transporter encoding gene MRP2/cMOAT/ABCC2 causes Dubin-Johnson syndrome in a Caucasian patient.

Materna V, Lage H. Materna V, et al. J Hum Genet. 2003;48(9):484-486. doi: 10.1007/s10038-003-0057-8. Epub 2003 Aug 27. J Hum Genet. 2003. PMID: 12942343

10

Significance of cyclooxygenase 2 and MDR1/P-glycoprotein coexpression in ovarian cancers.

Surowiak P, Materna V, Denkert C, Kaplenko I, Spaczyński M, Dietel M, Zabel M, Lage H. Surowiak P, et al. Among authors: materna v. Cancer Lett. 2006 Apr 28;235(2):272-80. doi: 10.1016/j.canlet.2005.04.035. Epub 2005 Jun 20. Cancer Lett. 2006. PMID: 15970376

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

33 results

Search Page

Filters